Mixed connective tissue disease, or MCTD, can be difficult to understand because it may include features of lupus, scleroderma, polymyositis, rheumatoid arthritis, or other autoimmune conditions.
PACT Rheumatology provides mixed connective tissue disease treatment in Connecticut for patients who need diagnosis, medication management, symptom monitoring, and ongoing care.
Accepting New Patients | Hamden, Guilford, and Orange, CT
Mixed connective tissue disease is a rare autoimmune disorder with features of several connective tissue diseases, including lupus, scleroderma, and polymyositis. Some patients may also have symptoms that resemble rheumatoid arthritis.
MCTD is often called an overlap syndrome because symptoms may involve more than one autoimmune disease pattern. It is commonly associated with high levels of U1-RNP antibodies in the blood.
Because symptoms can change over time, ongoing rheumatology monitoring is important.
MCTD symptoms vary depending on which body systems are involved. Symptoms may develop gradually and may not all appear at the same time.
Common symptoms may include:
Raynaud’s phenomenon refers to color changes in the fingers or toes, often turning white, blue, or red in response to cold or stress.
Pulmonary hypertension is one of the more serious complications that may occur in some patients with MCTD. Ongoing monitoring can help identify concerns that need additional evaluation.
MCTD and lupus are both autoimmune diseases, but they are not the same condition.
Lupus can affect many body systems and is often associated with antibodies such as anti-dsDNA or anti-Sm. MCTD is defined by overlapping features of several autoimmune diseases and is strongly associated with U1-RNP antibodies.
MCTD may include lupus-like symptoms, but it may also include features of scleroderma, polymyositis, or rheumatoid arthritis. A rheumatologist can review symptoms, antibody test results, and clinical findings to determine which diagnosis best fits.
The exact cause of mixed connective tissue disease is not fully understood. It is believed to develop when immune system changes cause inflammation and tissue-related symptoms.
Risk factors may include:
Having risk factors does not mean you will develop MCTD. A specialist evaluation is needed to understand symptoms and test results.
MCTD diagnosis is based on symptoms, exam findings, bloodwork, and monitoring over time. Because MCTD overlaps with other autoimmune diseases, diagnosis may require careful review.
Your provider may recommend:
MCTD can evolve over time, so follow-up visits may be needed to monitor symptoms and adjust care.
Hydroxychloroquine may be used for lupus-like symptoms, joint pain, fatigue, rashes, or flare prevention in some patients.
Anti-inflammatory medications or corticosteroids may be used to manage joint pain, swelling, muscle inflammation, or flares when appropriate.
Some patients may need medications that reduce immune system activity, especially when MCTD affects organs or causes more severe symptoms.
Medications such as calcium channel blockers may be considered for Raynaud’s symptoms when cold-triggered finger or toe color changes are frequent or disruptive.
Biologic therapy may be considered in select cases based on symptoms, diagnosis, and treatment response.
Because MCTD may involve the lungs or heart, PACT can coordinate evaluation with pulmonology, cardiology, or other specialists when needed.
PACT Rheumatology evaluates symptoms that may not fit neatly into one autoimmune disease category.
MCTD can evolve with time. Follow-up care helps track symptoms, labs, treatment response, and possible organ involvement.
PACT can coordinate with pulmonology, cardiology, primary care, or other specialists if MCTD affects the lungs, heart, muscles, or other systems.
Patients can access rheumatology care in Hamden, Guilford, and Orange, with service to surrounding Connecticut communities.
PACT provides a thoughtful approach for patients managing a less common autoimmune diagnosis that may require ongoing specialty care.
Mixed connective tissue disease can be complex, but specialist care can help clarify symptoms, monitor changes, and guide treatment.
Mixed connective tissue disease, or MCTD, is a rare autoimmune disorder with overlapping features of lupus, scleroderma, polymyositis, and sometimes rheumatoid arthritis.
Symptoms may include joint pain, swelling, Raynaud’s phenomenon, puffy fingers, fatigue, muscle weakness, skin changes, difficulty swallowing, shortness of breath, or organ-related concerns.
Lupus is one autoimmune disease that can affect many organs. MCTD includes overlapping features of lupus, scleroderma, polymyositis, and sometimes rheumatoid arthritis, and is strongly associated with U1-RNP antibodies.
MCTD is diagnosed through symptom review, physical exam, bloodwork such as ANA and U1-RNP antibody testing, and monitoring over time. Additional testing may be needed if organs are involved.
There is no current cure for MCTD, but treatment may help control symptoms, reduce inflammation, manage flares, and monitor for complications.
A rheumatologist usually diagnoses and treats MCTD because it is an autoimmune connective tissue disease with overlapping rheumatic symptoms.
MCTD can change over time, and some patients may develop features that resemble lupus, scleroderma, polymyositis, or rheumatoid arthritis. Ongoing rheumatology monitoring helps track these changes.
Yes. PACT Rheumatology provides mixed connective tissue disease treatment in Connecticut at locations in Hamden, Guilford, and Orange.
PACT, LLC & PACT MSO, LLC
322 East Main Street, Suite 1B
Branford, CT 06405
PACT, LLC & PACT MSO, LLC
322 East Main Street, Suite 1B
Branford, CT 06405
